TABLE 2.
Activity of orally-administered PTSAgs without endotoxin in monkeys
| Dose (μg/kg) | No. of animals with emesis (or diarrhea)/total no. of animals after an oral dose ofa:
|
||
|---|---|---|---|
| TSST-1 | SEC1 | SPEA | |
| 250 | ND | ND | 0/2 (0/2) |
| 100 | ND | ND | 0/2 (0/2) |
| 10 | 0/4 (4/4)b | 2/2 (2/2) | 0/2 (0/2) |
| 1.0 | 0/2 (1/2) | 2/4 (4/4) | ND |
| 0.1 | 0/2 (0/2) | 0/2 (0/2) | ND |
a
ND, not determined. Numbers in parentheses refer to the total number of animals with diarrhea/total number of animals.
b
Two sources of recombinant TSST-1 were used for this dose. Two animals received recombinant TSST-1 from S. aureus RN4220 and two additional animals received E. coli-derived recombinant TSST-1. No differences in symptoms were observed.